EHA 2024 | Novel targeted therapies for the treatment of BPDCN
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses novel targeted therapies for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), mentioning the FDA-approved agent tagraxofusp and the treatment options currently in development. Dr Qazilbash highlights that the only curative treatment strategy currently available for patients is allogeneic stem cell transplantation (alloSCT). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Sanofi, Janssen, Angiocrine; Advisory Board: Sanofi.
